Molecular weight dependent glucose lowering effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose level in SD rats model

International Journal of Molecular Sciences

Volumn 14, Issue 7, 2013, Pages 14214-14224

  Jo, Sung Hoon ^a   Ha, Kyoung Soo ^a   Moon, Kyoung Sik ^b   Kim, Jong Gwan ^c   Oh, Chen Gum ^c   Kim, Young Cheul ^d   Apostolidis, Emmanouil ^e   Kwon, Young In ^a  

^a Hannam University   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

^c Kunpoong Bio Co Ltd   (South Korea)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e FRAMINGHAM STATE UNIVERSITY   (United States)

Author keywords

glucosidase inhibition; Blood glucose; GO2KA1; Low molecular chitosan oligosacharide; Pre diabetes; Type 2 diabetes

Indexed keywords

ACARBOSE; AGENTS AFFECTING CARBOHYDRATE METABOLISM; AGENTS AFFECTING METABOLISM; ALPHA AMYLASE PANCREAS ISOENZYME; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; GLUCOSE; GO2KA1; GO2KA2; GO2KA3; UNCLASSIFIED DRUG; AMYLASE; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR; OLIGOSACCHARIDE;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; HYPERGLYCEMIA; METABOLISM; PIG; SMALL INTESTINE; SPRAGUE DAWLEY RAT;

ALPHA-AMYLASES; ALPHA-GLUCOSIDASES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLYCOSIDE HYDROLASE INHIBITORS; HYPERGLYCEMIA; INTESTINE, SMALL; OLIGOSACCHARIDES; RATS; RATS, SPRAGUE-DAWLEY; SWINE;

EID: 84880179292     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140714214     Document Type: Article

References (29)

1. Center for Disease Control. Available online: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf (accessed on 15 May 2011).
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabet. Care 1997, 20, 1183-1197.
3. Meigs, J.B.; Nathan, D.M.; D'Agostino, R.B., Sr.; Wilson, P.W. Framingham offspring study. Fasting and postchallenge glycemia and cardiovascular disease risk: The framingham offspring study. Diabet. Care 2002, 10, 1845-1850.
4. Smith, N.L.; Barzilay, J.I.; Shaffer, D.; Savage, P.J.; Heckbert, S.R.; Kuller, L.H.; Kronmal, R.A.; Resnick, H.E.; Psaty, B.M. Fasting and 2 hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: The Cardiovascular Health Study. Arch. Int. Med. 2002, 162, 209-216.
5. Coutinho, M.; Gerstein, H.C.; Wang, Y.; Yusuf, S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabet. Care 1999, 22, 233-240.
6. World Health Organization. Available online: http://www.who.int/mediacentre/factsheets/fs312/en/index.html (accessed on 6 April 2013).
7. Elsenhans, B.; Caspary, W.F. Absorption of Carbohydrates. In Amsterdam Excerptia Medica; Caspary, W.F., Ed.; Structure and Function of the Small Intestine: Amsterdam, Netherlands, 1987; pp. 139-159.
8. Krentz, A.J.; Bailey, C.J. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs 2005, 65, 385-411.
9. Andlauer, W.; Furst, P. Special characteristics of non-nutrient food constituents of plants-phytochemicals. Introductory lecture. Int. J. Vitam. Nutr. Res. 2003, 73, 55-62.
10. Apostolidis, E.; Kwon, Y.-I.; Shetty, K. Potential of cranberry-based herbal synergies for diabetes and hypertension management. Asia Pac. J. Clin. Nutr. 2006, 15, 433-441.
11. Kwon, Y.I.; Vattem, D.A.; Shetty, K. Clonal herbs of Lamiaceae species against diabetes and hypertension. Asia Pac. J. Clin. Nutr. 2006, 15, 107-118.
12. Kwon, Y.I.; Apostolidis, E.; Kim, Y.C.; Shetty, K. Health benefits of traditional corn, beans and pumpkin: In vitro studies for hyperglycemia and hypertension management. J. Med. Foods 2007, 10, 266-275.
13. Huang, R.; Mendis, E.; Kim, S.K. Improvement of ACE inhibitory activity of chitosanoligosacchiarides (COS) by carboxyl modificatrion. Bioorg. Med. Chem. 2005, 23, 3649-3655.
14. Maezaki, Y.; Tsuji, K.; Nakagawa, N.; Kawai, Y.; Akimoto, M.; Tsugita, T.; Takekawa, W.; Terada, A.; Hara, H.; Mitsoka, T. Hypocholestromic effect of chitoan in adult males. Biosci. Biotech. Biochem. 1993, 57, 1439-1446.
15. Okamoto, Y.; Inoue, A.; Miyatake, K.; Ogihara, K.; Sigemasa, Y.; Minami, S. Effect of chitin/chitosan and their oligomers/monomers on migration of macrophages. Macromol. Immunol. 2003, 33, 357-367.
16. Kim, S.K.; Rajapaske, N.; Shahidi, F. Production of Bioactive Chitosan Oligosaccharides and Their Potential Uses as Nutraceuticals. In Marine Nutraceuticals and Functional Foods; Barrow, C., Shahidi, F., Eds.; CRC Press, Taylor & Francis Group: Boca Raton, FL, USA, 2008; pp. 183-196.
17. Lim, S.H.; Hudson, S.M. Review of chitosan and its derivatives as antimicrobial agents and their uses as textile chemicals. J. Macromol. Sci. 2003, C43, 223-269.
18. Hall, G.; Lund, L.; Lamb, J.R.; Jarman, E.R. Kinetics and mode of peptide delivery via respiratory mucosa determine the outcome of activation versus TH2 immunity in allergic inflammation of the airways. J. Allerg. Clin. Immunol. 2002, 110, 883-890.
19. Kim, M.S.; Sung, M.J.; Seo, S.B.; Yoo, S.J.; Lim, W.K.; Kim, H.M. Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid beta peptide and interleukin-1beta. Neurosci. Lett. 2002, 321, 105-109.
20. Kim, M.S.; You, H.J.; You, M.K.; Kim, M.S.; Shim, B.S.; Kim, H.M. Inhibitory effect of water-soluble chitosan on TNF-alpha and IL-8 secretion from HMC-1 cells. Immunopharmacol. Immunotoxicol. 2004, 26, 401-409.
21. Theocharides, T.C.; Cochrane, D.E.; Critical role of mast cells in inflammatory disease and the effect of acute stress. J. Neuroimmunol. 2004, 146, 1-12.
22. Nishimoto, N.; Kishimoto, T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. 2004, 4, 386-391.
23. Synowiecki, J.; Al-Khateeb, N.A. Production, properties, and some new applications of chitin and its derivatives. Critic. Rev. Food Sci. Nutr. 2003, 43, 145-171.
24. Kondo, Y.; Nakatani, A.; Hayashi, K.; Ito, M. Low molecular weight chitosan prevents the progression of low dose streptozotocin-induced diabetic mice. Biol. Pharm. Bull. 2000, 23, 1458-1464.
25. Kim, Y.C.; Kim, S.H.; Yoon, S.P.; Kim, J.W. Reducing effect of chitosan oligosaccharide on postprandrial blood glucose level in Koreans. J. Chitin Chitos. 2009, 14, 107-111.
26. Bischoff, H.; Puls, W.; Krause, H.P.; Schutt, H.; Thomas, G. Pharmacological properties of the novel glucosidase inhibitors BAY m 1099 (miglitol) and BAY o 1248. Diabetes Res. Clin. Pract. 1985, 1, 53-62.
27. Horii, S.; Fukasse, K.; Matrua, T.; Kameda, K.; Asano, N.; Masui, Y. Synthesis and α-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potent oral antidiabetic agents. J. Med. Chem. 1987, 29, 1038-1046.
28. Jang, M.K.; Kang, S.K.; Nah, J.W. Absorption behavior in the body of chitosan oligosaccharide according to molecular weight; An in vitro and in vivo study. Food Sci. Biotechnol. 2006, 15, 937-941.
29. Chae, S.Y.; Jang, M.K.; Nah, J.W. Influence of molecular weight on oral absorption of water soluble chitosans. J. Control. Release 2005, 102, 383-394.